NCT02686788 - TMP001 in Relapsing-remitting Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions

Remitting-Relapsing Multiple Sclerosis

Interventions

DRUG

TMP001

600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks

Trial Locations (5)

Charite- Universitätsmedizin Berlin (Campus Mitte) NeuroCure Clinical Research Center NCRC AG Klinische Neuroimmunologie, Berlin

Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster

Goethe-Universität Frankfurt am Main, Frankfurt am Main

Universitätsklinikum Heidelberg Neurologische Klinik, Heidelberg

UKT, Universitätsklinikum Tübingen, Tübingen

All Listed Sponsors

collaborator

SocraMetrics GmbH

INDUSTRY

lead

Dr. Frank Behrens

OTHER